Trial · NCT00533273
Results by group56
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 56
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Reduction in Primary Joint Contracture to 5° or Less | AA4500 0.58 mg | 44.4 | Percentage of Joints | ||
| Reduction in Primary Joint Contracture to 5° or Less | Placebo | 4.8 | Percentage of Joints | ||
| Clinical Improvement in Primary Joint After the Last Injection | AA4500 0.58 mg | 77.8 | Percentage of Joints | ||
| Clinical Improvement in Primary Joint After the Last Injection | Placebo | 14.3 | Percentage of Joints | ||
| Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection | AA4500 0.58 mg | 70.5 | Standard Deviation 29.21 | Percentage of change | |
| Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection | Placebo | 13.6 | Standard Deviation 26.10 | Percentage of change | |
| Change From Baseline Range of Motion in Primary Joint After the Last Injection | AA4500 0.58 mg | 35.4 | Standard Deviation 17.77 | Degrees | |
| Change From Baseline Range of Motion in Primary Joint After the Last Injection | Placebo | 7.6 | Standard Deviation 14.88 | Degrees | |
| Time to Reach Clinical Success in Primary Joint | AA4500 0.58 mg | Injection 1, Day 1 | 2.2 | Percentage of Joints | |
| Time to Reach Clinical Success in Primary Joint | Placebo | Injection 1, Day 1 | 0.0 | Percentage of Joints | |
| Time to Reach Clinical Success in Primary Joint | AA4500 0.58 mg | Injection 1, Day 7 | 6.7 | Percentage of Joints | |
| Time to Reach Clinical Success in Primary Joint | Placebo | Injection 1, Day 7 | 4.8 | Percentage of Joints | |
| Time to Reach Clinical Success in Primary Joint | AA4500 0.58 mg | Injection 1, Day 30 | 17.8 | Percentage of Joints | |
| Time to Reach Clinical Success in Primary Joint | Placebo | Injection 1, Day 30 | 0.0 | Percentage of Joints | |
| Time to Reach Clinical Success in Primary Joint | AA4500 0.58 mg | Injection 2, Day 1 | 0.0 | Percentage of Joints | |
| Time to Reach Clinical Success in Primary Joint | Placebo | Injection 2, Day 1 | 0.0 | Percentage of Joints | |
| Time to Reach Clinical Success in Primary Joint | AA4500 0.58 mg | Injection 2, Day 7 | 4.4 | Percentage of Joints | |
| Time to Reach Clinical Success in Primary Joint | Placebo | Injection 2, Day 7 | 0.0 | Percentage of Joints | |
| Time to Reach Clinical Success in Primary Joint | AA4500 0.58 mg | Injection 2, Day 30 | 8.9 | Percentage of Joints | |
| Time to Reach Clinical Success in Primary Joint | Placebo | Injection 2, Day 30 | 0.0 | Percentage of Joints |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00533273/results